Also known as Kerendia.
FDA acceptance of finerenone sNDA for adults with CKD without diabetes follows Phase III FIND‑CKD showing slower eGFR decline and reduced cardio‑kidney events versus placebo.
FDA clears finerenone to reduce UACR in adults with CKD linked to type 1 diabetes, aiming to slow eGFR decline and lower risk of end‑stage kidney disease.
